exosomes Archives | Page 11 of 12

Exosome Market Forces

March 23, 2018 By Cade Hildreth, Founder & President 2 Comments

Exosome-related technologies have been developing rapidly over the past few years and substantial growth is expected for the market as they get integrated into the fields of liquid biopsy, precision medicine and regenerative medicine.

In particular, cancer derived exosomes influence the invasive potential of cells by regulating angiogenesis, metastasis, and immunity, making them an extremely useful source of biomarkers for use in cancer detection, diagnosis, and therapeutic selection. [Read more…]

Avalon GloboCare Subsidiary GenExosome Expands Exosome Operations into the U.S.

February 14, 2018 By Cade Hildreth, Founder & President Leave a Comment

FREEHOLD, NJ–(February 14, 2018) – Avalon GloboCare Corp. (OTCQB: AVCO), a leading global developer of cell-based technologies, announced today that its majority-owned subsidiary, GenExosome Technologies Inc. (GenExosome), has formally launched its U.S. operations, with plans to market and distribute its proprietary Exosome Isolation Systems from its new headquarters in Ohio. The Company also announced plans to develop proprietary diagnostic and therapeutic products leveraging its exosome technology. The Company has already begun hiring personnel for marketing and customer fulfillment.

Exosomes are tiny, subcellular, membrane-bound vesicles, measuring 30-150 nm in diameter, that are released by almost all cell types. Exosomes can carry membrane and cellular proteins, as well as genetic materials that are representative of the cell of origin. Profiling various bio-molecules in exosomes may serve as useful biomarkers for a wide variety of diseases.

GenExosome’s Exosome Isolation Systems are designed to be used by researchers for biomarker discovery and clinical diagnostic development, as well as the advancement of targeted therapies. Currently, research kits and services are available to isolate exosomes or extract exosomal RNA/protein from serum/plasma, urine and saliva samples. GenExosome is seeking to decode proteomic and genomic alterations underlying a wide-range of pathologies, thus allowing for the introduction of novel non-invasive liquid biopsies. [Read more…]

Salivary EVs, Exosomes, and the Future of Non-Invasive Diagnostics

February 6, 2018 By Cade Hildreth, Founder & President 1 Comment

I had the honor of interviewing Paul D Slowey, PhD, CEO of Oasis Diagnostics® Corporation, a company specializing in non-invasive saliva based technology for rapid testing, sample collection, and molecular diagnostics. Dr. Slowey is also the Organizer of the North American Saliva Symposium (NASS).

In this interview, we discuss his unique background, the rise of extracellular vesicles (EVs) and exosomes as diagnostic tools, advantages of saliva over other bodily fluids, and current and future applications for saliva-derived EVs and exosomes. [Read more…]

Will Exosomes Go Exponential? Exosome Companies Are Multiplying Fast

January 20, 2018 By Cade Hildreth, Founder & President 1 Comment

With 25% of all exosome publications released in the past year and exosome companies flooding into the marketplace, we are witnessing an exosome explosion. Exosomes are small vesicles ranging from 30-100nm in size that are found in nearly all eukaryotic fluids and facilitate a range of important cellular functions. Specifically, they transfer DNA, RNA, and proteins to other cells, thereby altering the function of the targeted cells.

Exosomes are commonly found in blood, urine, and saliva, among other fluids. Exosomes are also present in other body fluids, such as synovial fluid, amniotic fluid, semen, vaginal fluid, breast milk, and more.

It has been long known that stem cells have the potential to exert therapeutic effects, but it has only been recently recognized that exosomes play an important role how stem cells exert their cellular functions. [Read more…]

Exosome Manufacturing: $2.18M Grant Awarded to VivaZome Therapeutics

January 13, 2018 By Cade Hildreth, Founder & President Leave a Comment

$2.18m grant awarded to VivaZome Therapeutics for Exosome Therapy; Grant awarded in collaboration with La Trobe University and SeerPharma

18 December 2017, Geelong – Melbourne, Australia: Australian biotech company VivaZome Therapeutics is pleased to announce that it has been awarded an Australian Government CRC-P grant of $2.18m in support of the project “Enabling Exosome Therapy: Developing an Advanced Manufacturing Process”, with the funds provided under the Advanced Manufacturing Scheme.

The Hon Craig Laundy MP (Assistant Minister for Industry, Innovation and Science) oversees the Cooperative Research Centre Projects (CRC-P) Grants Scheme which supports the development of innovative Australian companies and sectors.

Joining VivaZome in the CRC-P are La Trobe University and SeerPharma Pty Ltd, each of which bring high-level scientific and operational skills to the 3 –year project. VivaZome will also engage with the CSIRO to provide expertise in industrial–scale manufacturing. [Read more…]